<SEC-DOCUMENT>0001019687-15-003733.txt : 20151016
<SEC-HEADER>0001019687-15-003733.hdr.sgml : 20151016
<ACCEPTANCE-DATETIME>20151016080013
ACCESSION NUMBER:		0001019687-15-003733
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20151015
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20151016
DATE AS OF CHANGE:		20151016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SIMULATIONS PLUS INC
		CENTRAL INDEX KEY:			0001023459
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
		IRS NUMBER:				954595609
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32046
		FILM NUMBER:		151161093

	BUSINESS ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		STREET 2:		*
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
		BUSINESS PHONE:		661-723-7723

	MAIL ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>simulations_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>UNITED STATES</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">FORM 8-K</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">October 15, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-weight: normal">(Date of the
earliest event reported)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Simulations Plus, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-weight: normal">(Exact name
of registrant as specified in its charter)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%; text-align: center"><B>California</B></TD>
    <TD STYLE="width: 34%; text-align: center"><B>001-32046</B></TD>
    <TD STYLE="width: 33%; text-align: center"><B>95-4595609</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center"><FONT STYLE="font-weight: normal">(State
or other jurisdiction of incorporation)</font></TD>
    <TD STYLE="text-align: center"> (Commission File Number)</TD>
    <TD STYLE="text-align: center"> (I.R.S. Employer Identification No.)</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">42505 10<SUP>th</SUP> Street West, Lancaster,
California 93534-7059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-weight: normal">(Address of
principal executive offices) (Zip Code)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">661-723-7723</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-weight: normal">Registrant's
telephone number, including area code</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[
&nbsp;] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[
&nbsp;] Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[
&nbsp;] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b)) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[
&nbsp;] Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in"><B>Item 8.01<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
Events</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
October 15, 2015, Simulations Plus, Inc., a California corporation (the &quot;Company&quot;), issued a press release announcing
it is expanding its software offerings for pharmaceutical research and development with PKPlus&trade;</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
new program that provides high-quality, user-friendly analysis and reporting of clinical trial data for use in submissions to regulatory
agencies. The program is expected to be beta released in November, with full release expected in January 2016. The press release
is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information contained in this Current Report
on Form 8-K shall not be deemed to be &quot;filed&quot; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the &quot;Exchange Act&quot;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or the Exchange Act,
except as shall be expressly set forth by specific reference in such a filing. The information set forth in this Current Report
on Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Current Report on Form
8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Current Report on Form 8-K may contain
forward-looking statements that are made pursuant to the safe harbor provisions of Section 21E of the Exchange Act. The forward-looking
statements in this Current Report on Form 8-K are not historical facts, do not constitute guarantees of future performance and
are based on numerous assumptions which, while believed to be reasonable, may not prove to be accurate. Any forward-looking statements
in this Current Report on Form 8-K do not constitute guarantees of future performance and involve a number of factors that could
cause actual results to differ materially, including risks more fully described in our most recently filed Quarterly Report on
Form 10-Q and Annual Report on Form 10-K. The Company assumes no obligation to update any forward-looking information contained
in this Current Report or with respect to the announcements described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">99.1</TD><TD>Press release issued on October 15, 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">SIMULATIONS PLUS, INC.</TD>
</TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">Dated: October 15, 2015</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/ John R. Kneisel</TD>
</TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">John R. Kneisel<BR>Chief Financial Officer</TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>simulations_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For Further Information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">42505 10<SUP>th</SUP> Street West</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Lancaster, CA 93534-7059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>CONTACT</B>:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><U>Simulations Plus Investor Relations</U></TD>
    <TD STYLE="width: 50%"><U>Hayden IR</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Ms. Renee Bouche</TD>
    <TD>Mr. Cameron Donahue</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>661-723-7723</TD>
    <TD>651-653-1854</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><U>renee@simulations-plus.com</U></TD>
    <TD><U>cameron@haydenir.com</U></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For Immediate Release:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">October 15, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Simulations Plus to Launch Major New Software
Product</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PKPlus&trade; Will Provide Analysis Capability
Required for Regulatory Submissions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>LANCASTER, CA, October 15, 2015 &ndash;
</B>Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and
development, today announced it is expanding its offerings of best-in-class software for pharmaceutical research and development
with PKPlus&trade;, a new program that provides high-quality, user-friendly analysis and reporting of clinical trial data for use
in submissions to regulatory agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">John DiBella, vice president for marketing
and sales for Simulations Plus, said: &ldquo;We believe PKPlus represents a major addition to our product line with the potential
to become one of our leading sources of revenues and earnings. Many in the industry have been under the mistaken impression that
there is only one software program that meets the requirements of regulatory agencies for analysis and reporting of noncompartmental
analysis results for clinical trial data. We intend to correct that misconception. We have taken the core elements of our PKPlus
Module, originally introduced as an optional module in our flagship <U>GastroPlus&trade;</U> software over 15 years ago, and are
turning it into a standalone program that will provide:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">calculation of pharmacokinetic parameters using noncompartmental analysis,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">calculation of pharmacokinetic parameters using compartmental analysis with 1, 2, or 3 compartments,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">support for importing and exporting common data file types,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">data management functions to deal with organizing and examining data,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">highly flexible selection of records to analyze and compare desired subsets of a total data set,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">production of high-quality tables, figures, and listings for export to reporting programs,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">audit trail (saving all software settings) to ensure the ability to duplicate results from submitted
analyses in the future.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Walt Woltosz, CEO of Simulations Plus and its
wholly owned subsidiary, Cognigen Corporation, said, &ldquo;We are designing PKPlus to be a friendly but powerful program to satisfy
pharmaceutical researchers&rsquo; needs while providing better value than alternative programs. The development of PKPlus is an
excellent illustration of the synergies between Simulations Plus and our Cognigen subsidiary. We expect a beta release of PKPlus
in November, with full release expected in January, but we are announcing it now in order to be able to discuss it at our annual
Japan User Meeting for this year in Tokyo tomorrow as well as at the 2015 American Association of Pharmaceutical Scientists Annual
Meeting in Orlando, Florida, starting on October 25.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Simulations Plus, Inc., is a premier developer
of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research
by major pharmaceutical and biotechnology companies worldwide. For more information, visit our Web site at <U>www.simulations-plus.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cognigen Corporation, a wholly owned subsidiary
of Simulations Plus, Inc., is a leading provider of population modeling and simulation contract research services for the pharmaceutical
and biotechnology industries. For more information, visit Cognigen&rsquo;s website at <U>www.cognigencorp.com<FONT STYLE="color: blue">.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: blue">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The combined company is a global leader focused
on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology
agents. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical
science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic
modeling and simulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Safe Harbor Statement Under the Private
Securities Litigation Reform Act of 1995</B> &ndash; With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks and uncertainties. Words like &ldquo;believe,&rdquo;
&ldquo;expect&rdquo; and &ldquo;anticipate&rdquo; mean that these are our best estimates as of this writing, but that there can
be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ
significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to:
our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by
our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company,
and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with
the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">###</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !' -T# 2(  A$! Q$!_\0
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M/XD^"7>30O$5E&)&A#?>BEC)'F1D]L\98<AF4^2>/?V$?V@?VC]2\'67Q/\
MBKX'N_#WA#Q!:>(4&E: R7=Y-;D[=Q^15R&8<<<]#BO6HU,%75*5>2Y8QY7%
M\UU9MWCRZ._GUO='F588NBZD:,7>4N927+9[*TKZJWETMJ?;5?FI^RKXL^.'
MAW]J#]I9/A1X4\$>(M/D\?W)OY-<U*2UDAEW2;50*>5QW/>OTKKXJT+]A;X^
M?!_XR?$OQ!\.OBAX*T33/B)XAGUV6UOM$:ZDC+LQ12S \A6P<<$UR9/6I0A6
MA4<?>2MS7MHT_LZG5FM*I*=*=-2]UN_+:^UNNA];?"R^\1ZE\.](G\7V.G:;
MXFEME;4K6PF,UM!-W6-SR5^M?#7_  4A_9UTO]J[_@HK\._ >JD0IKW@+6$M
MKK;EK&Y3S)(9U]UD521W&1WK[5^!6B>,_#OPQL+3Q_K>E^(O%4;2_:[_ $ZS
M^R6\P,C&,+'V(0J#ZD$]ZX'X@?LKZCXQ_;J\ _%J+5;*'3?!^AWNE36#1L9[
MAIQ( RM]T ;QU]#ZUGE^)6&Q4ZJDDTIV:O:]G:W7?:_S+QV'>(PT*;BW=QNG
M:]KJ]_EO8^!/&G[2NN_%CP7\#/A]X^#0?%+X0_&31=#\01R-E[R(>8MO> _Q
M"15(+?Q%=W1Q7ZG_ ! &O/X-U!?#!TM-?>$K92:EO-K%(> \@3YF5>NT8SC&
M1G(^8_VQO^"8%K^T;^U=\./BSH6JV>@:UX5U.SN=:CEA9UUB"VG26+&WI*H5
MDW'JI7^X,_6M;9KB\/5A1E0\VX]$V[M>G;RT,LLPM>E.K&MY)/NDM'Z]_,_/
MVW_X('>'_B;XXO\ Q;\6_B5XL\=^)]7E-Q>RVT<=A!(YQQ@^8X10 %"LH
M  %>F>#O^"+/P4\$!#8V6L0RQ\":.XC6;'M+L,@^JN*^MJ*PJ9]F$U9U7;LM
M%]RT-J>2X&&JIJ_=ZO[WJ<C\%/@AH'[/_@O^P/#B:@FGFX>Z;[;?S7LK2/C<
M3),S-V'&<#L*ZZBBO*G.4Y.4W=L]*$(PBHQ5D@HHHJ2@HHHH \V^*G[1T?P]
M\?6GA?3/"WB;QEKTME_:EU:Z/'!_Q+[,R&-9I7FEC7YG5PJ*2S>6_'%>A3W\
M=NB[CAW4LD>1O? R0!W-?,W[>/B3PQX%\01^(=*\8ZAX3^,NE:-)_P (_;64
M+W!\3H7+1Z=+;;"MU&\RX"KB2,N6#+DDYWPXO/!][^U'XJ?XHV=K;_%:?5;>
M3PI%J2/(8; V,)B73F(VX68W(E,?.\-OXVUZJP,9T8U(IK1]'=NZ^5M=U\SS
M?KCC6=-M;KJK+?YWTV?R/IGP;XP7Q;X2TO59;'4-$;5(ED6QU.,07<#,,^7(
MF2 X[@$UJM<QK*J%T#N2%4MRV.3@5^:EAH,FN?#[P1IWC'7/#/A:ROOAII=M
MX:U+Q-IMY.UG>EI_M,EE(DL:Q7R/]F;G,A CV_*&%>C^/_A);^9\6/&=W:WE
M]XV\+_$+P^FD:P!*)K51%HR3-;J#A$DWS>8%X8,0V=HQT3RB"GR\_P"'FDM;
M^>O:QC#,YN'-R?CY-O2WEIWN?<AN8Q<"+>GFE=P3=\Q'KCTHAN8[D-Y;H^UB
MC;6S@CJ#[U\1ROI+Z%\88X8?^,F#/XA.G&XBD.K&VQ,+/[ QY^S_ &+RMGED
M+OS_ !YKH_V.?$G@OX9:WJ.OZ?XR\%'0=:CTGP__ &-X8T:\MHH=1DED2"6Y
M2225EN9 WEN6"M^[4R'(!K"IEG+!R3=UY;_\!]'ULS:&8\TU%I6?GM_P5U70
M]S^*G[1\?P]\?6WA?2_"OB?QEKSV0U2ZM=&C@_XE]H9#$LLCS2QKEG5PJ*2S
M>6_&!7HINHUE2-G59) 2J%AN;'7 ]J^8OV\/$OACP'XC3Q#I/C'4/"?QFTK1
MG_L"ULX7N#XHC,C-%ITMMM*W4;S*0 N)(C(7#*"<^5_&A['4=7^(W]OV5U!\
M?[K7].F\"QHLCWL,'EVAMA8N!C[,DGVG[05.WB;S."*NEET:L(26E_)WW2OV
MY5?=?,BICY4IR3UMYZ;/3OS:;/Y'TYH_[6.G7_Q \06-UI[:;X;T36H?#$6N
M372D:AJTAB'V:.!07"@RJ/-8A=RL,8&:]76577(8$9QD&O@7QU\!O 6A?#3Q
MMK>L^$-%ATNQ^-=O/JMU-IV4CL%NX%DDDXSY(6:7+= '8],UK_%?1-5\-_%7
MQ-I7AZ&^_P"$>\#7<7Q@L/LRR>3<QK!;QBT0KPP=HK]A&,]5XZ5I/+:4VO9.
MWJM-.7SWNS.&858)^T5_1ZZW\MM#[@EO(H64/+&I=MBAF W-Z#W]J?YR"0+N
M7<>@SR:_.;]H34XA\#+73]7TS0K#Q!XG\+ZSX\L=6U;2[B^U*2^O+E[B*QTU
M8V0Q7<:^1E\EHPL>$(#$=?\ $KP%J.O:=\;_ !A;VM]<^(XQX=M6N6BN)S;:
M;+8Z<^I^3%$5<[XA)YOE$.RIM!R!4_V.K)N=KZ;?WDN^VORL5_:CUM#;S\F^
MWD?=-O<QW<(DB=)(VZ,C9!_&O./$?[2$>G_&%_!ND>%?$_B>ZT_[*=9O-.C@
M%KH@N"?*\UI949CM!<K&KE4P3U /EO[&OB;PG\.KC4/L/C'P=J6E^/M<BL]&
MTWPIID]OI5C>QV323(BEY!&TD<0=N57<I_B8YS_VJ?%^A?#GX\1ZQX$\4W]C
M\8II],L;OPK;QO-;^+K5I5 2> J1^[ADE(NHRIB"D,Q VUC3P*5=TFF]--&E
MTWZI+57VOY&L\8_8JJFEKKJG]W2[T=NWF?57FK_>'7'7OZ4@N8VG,0=#*H#%
M-WS 'OBOB&#XA6=IXFT[P'YU^?%NG?'*?4KK3Q!,9+:QFN[B>"YD.,+;NDL>
MUR=I+;1R#C$T&7PRW[*_B1;2"^_X7DJ*?B%Y,,W_  DYM#J<']J[6 \PQFW\
MSRO+./+V>7VK3^R'U>[2VZ/KOMY^A']J+HNCZ]NFV_D?>O\ :5N+<S>?#Y2G
M:7WC:#G&,].O%227,<4J(SHKRYV*6P7QUP.]?#'QBD^&4R> 6\#/\-[/X.-)
MJB:A+?Z7-<^'AK!BM5@^TK$\867R/."/*<!\C_6%:L^'M*TWX4?&/X/2/XB\
M._%/6+G2M-T9+6XM)O[4TRT+W#Q:MIS,7*QK')B??RR0(3)NPK+^RER<W,[Z
MZ./:^_1;=^H_[2?-:RMIK?O;;J]S[=BNHYW=4D1S&=KA6!*'T/I4E?(G[#?Q
M+\)_!^^U_P -+>>'M8L)=4T_3K'QEI%E-YGB6[NVN3';WYVMF^C\LF23=MQ,
MA/ED[:^NZX<7AG0J.'3H[6O_ %_PYV87$*M3Y^OWA1117*= 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
